Human cytochromes P450 in the metabolism of drugs: New molecular models of enzyme - substrate interactions

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 9, 2008, Pages 1181-1186

  Lewis, David F V ^a   Ito, Yuko ^b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Cytochromes P450; Drug metabolism; Enzyme structures; Molecular modelling

Indexed keywords

AMODIAQUINE; BUFURALOL; CLOPIDOGREL; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DICLOFENAC; DRUG METABOLIZING ENZYME; FLUCONAZOLE; FLUINDOSTATIN; MEPHENYTOIN; METHOXSALEN; NICOTINE; OMEPRAZOLE; PILOCARPINE; PROGUANIL; PROPRANOLOL; QUERCETIN; ROSIGLITAZONE; SELEGILINE; THIORIDAZINE; TIENILIC ACID; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

AEROBIC METABOLISM; BINDING SITE; CRYSTAL STRUCTURE; DRUG BINDING; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; ENZYME BINDING; ENZYME KINETICS; ENZYME STRUCTURE; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; HUMAN; MOLECULAR MECHANICS; MOLECULAR MODEL; REVIEW; STRUCTURE ANALYSIS;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; XENOBIOTICS;

EID: 52649175489     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.9.1181     Document Type: Review

References (48)

1. Lewis DFV. Guide to cytochromes P450 structure and function. Taylor & Francis: London; 2001
2. Lewis DFV, Sheridan G. Cytochromes P450, oxygen and evolution. Sci World 2001;1:151-67
3. Lewis DFV, Ito Y, Goldfarb PS. Structure and function of the cytochromes P450. Curr Med Chem 2006;13:2645-52
4. Guengerich FP. Human cytochrome P450 enzymes. Chapter 10. In: Ortiz de Montellano PR, editor, Cytochrome P450. Kluwer/Plenum: New York, 2005. p. 377-530
5. Hrycay EG, Bandiera SM. Cytochrome P450 enzymes. Chapter 18. In: Gad SC, editor, Preclinical development handbook: ADME and biopharmaceutical properties. John Wiley: New York, 2008. p. 627-96
6. Lewis DFV. Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Curr Med Chem 2003;10:1955-72
7. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002;34;83-448
8. Rendic S, DiCarlo FJ. Human cytochrome P450 enzymes: a status report summarising their reactions, substrates, inducers and inhibitors. Drug Metab Rev 1997;29:413-580
9. Lewis DFV. 57 varieties: the human cytochromes P450. Pharmacogenomics 2004;5:305-18
10. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP2A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91
11. Lewis DFV, Dickins M. Substrate SARs in human P450s. Drug Discov Today 2002;7:918-25
12. Lewis DFV, Ito Y. Cytochrome P450 structure and function: an eVolumetionary perspective. Chapter 1. In: Ioannides C, editor, Cyrochromes P450. RSC: London; 2008
13. Rowland P, Blaney FE, Smyth MG, et al. Crystal structure of human cytochrome P4502D6. J Biol Chem 2006;281:7614-22
14. Scott EE, White MA, He YA, et al. Structure of mammalian cyrochrome P4502B4 complexed with 3-(4-chlorophenyl)imidazole at 1.9Å resolution. J Biol Chem 2004;279:27294-301
15. Wester MR, Johnson EF, Marques-Soares C, et al. Structure of mammalian cytochrome P4502C5 complexed with diclofenac at 2.1Å resolution: evidence for an induced fit model of substrate binding. Biochemistry 2003;42:9335-45
16. Wester MR, Yano JK, Schoch GA, et al. The structure of human cytochrome P4502C9 complexed with flurbiprofen at 2.0Å resolution. J Biol Chem 2004;279:35630-7
17. Williams PA, Cosine J, Vinkovic DM, et al. Crystal structures of human cytochrome P4503A4 bound to metyrapone and progesterone. Science 2004;305:683-6
18. Poulos TL, Johnson EF. Structures of cytochrome P450 enzymes. Chapter 3. In: Ortiz de Montellano PR, editor, Cytochrome P450. Kluwer/Plenum: New York; 2005. p. 87-114
19. Lewis DFV. Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica 2002;32:305-23
20. Lewis DFV. Modelling human cytochrome P450 involved in drug metabolism from the CYP2C5 crystallographic template. J Inorg Biochem 2002;91:502-14
21. Lewis DFV. Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys 2003;409:32-44
22. Lewis DFV. Structural models for cytochrome P450-mediated catalysis. Sci World 2003;3:536-45
23. Lewis DFV. P450 structures and oxidative metabolism of xenobiotics. Pharmacogenomics 2003;4:387-95
24. Lewis DFV, Ito Y, Goldfarb PS. Enzyme-substrate binding interaction energies and their application to the cytochrome P450 system. Curr Comput Aided Drug Des 2008;4:111-22
25. Ito Y, Kondo H, Goldfarb PS, Lewis DFV. Analysis of CYP2D6 substrate interactions by computational methods. J Mol Graph Model 2008;26:947-56
26. De Groot MJ, Kirton SB, Sutcliffe MJ. In silico methods for predicting ligand binding determinants of cytochromes P450. Curr Top Med Chem 2004;4:1803-24
27. De Groot MJ, Lewis DFV, Modi S. Molecular modelling and Quantitative Structure-Activity Relationship (QSAR) of substrates and inhibitors of drug metabolism enzymes. Chapter 34. In: Testa B, van de Waterbeemd H, editors, Comprehensive medicinal chemistry II. Volume 5. Elsevier: Amsterdam; 2006. p. 809-25
28. Afzelius L, Hasselgren Arnby C, Carlsson L, et al. State-of-the-art tools for computational site of metabolism predictions: comparative analysis, mechanistical insights and future applications. Drug Metab Rev 2007;39:61-86
29. Lewis DFV, Ito Y, Goldfarb PS. Investigating human P450s involved in drug metabolism via homology with high-resolution P450 crystal structures of the CYP2C subfamily. Curr Drug Metab 2006;7:589-98
30. Lewis DFV, Ito Y, Goldfarb PS. Cytochrome P450 structures and their substrate interactions. Drug Dev Res 2006;66:19-24
31. Obach RS, Reed-Hagen AE. Measurement of Michaelis constant for cyrochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 2002;30:831-7
32. Lewis DFV. Hydrogen bonding in human P450-substrate interactions: a major contribution to binding affinity. Sci World 2004;4:1074-80
33. D values. Curr Drug Metab 2003;4:331-40
34. Lewis DFV, Jacobs MJ, Dickins M. Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discov Today 2004;9:530-7
35. Makris TM, Denisov I, Schlichting I, Sligar SG. Activation of molecular oxygen by cytochrome P450. Chapter 5. In: Ortiz de Montellano PR, editor, Cytochromes P450. Kluwer/Plenum: New York; 2005. p. 149-82
36. Lewis DFV, Dickins M. Factors influencing rates and clearance in P450-mediated reactions: QSARs for substrates of the xenobiotic-metabolizing hepatic microsomal P450s. Toxicology 2002;170:45-53
37. Shaik S, De Visser SP. Computational approaches to cytochrome P450 function. Chapter 2. In: Ortiz de Montellano PR, editor, Cytochrome P450. Kluwer/Plenum: New York; 2005. p. 45-85
38. cam: theory supports a two-state rebound mechanism. J Am Chem Soc 2004;126:4017-34
39. Schoch GA, Yano J, Wester MR. Structure of human microsomal cytochrome P4502C8. J Biol Chem 2004;279:9497-503
40. Yano JK, Hsu M-H, Griffin KJ, et al. Structures of human microsomal cyrochrome P4502A6 complexed. with coumarin and methoxsalen. Nat Struct Mol Biol 2005;12:822-3
41. Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 1999;57:465-80
42. Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human popluations from in vitro data. Nat Reserves (Drug Discov) 2007;6:140-8
43. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacol 1997;32:210-58
44. Hewitt NJ, Gomez Lechon MJ, Houston JB, et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance and hepatotoxicity studies. Drug Metab Rev 2007;39:159-234
45. Mestres J. Structure conservation in cyrochromes P450. Proteins Struct Funct Bioinform 2005;58:596-609
46. Cruciani G, Carosati E, De Boeck B, et al. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. J Med Chem 2005;48:6970-9
47. Terfloth L, Bienfait B, Gasteiger J. Ligand-based models for the isoform specificity of cyrochromc P450 3A4, 2D6 and 2C9 substrates. J Chem Informatics Model 2007;47:1688-1701
48. Kemp CA, Flanagan JU, van Eldik AJ, et al. Validation of model of cyrochromes P450 2D6: an in silico tool for predicting metabolism and inhibition. J Med Chem 2004;47:5340-6